首页 | 本学科首页   官方微博 | 高级检索  
检索        


Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients
Authors:Nabhan Chadi  Davis Nancy  Bitran Jacob D  Galvez Angel  Fried Walter  Tolzien Kathy  Foss Susan  Dewey Wendy M  Venugopal Parameswaran
Institution:Division of Hematology and Medical Oncology and Hematology and Oncology Fellowship Program, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA. Illinois. cnabhan@oncmed.net
Abstract:

BACKGROUND:

Currently, no standard therapy exists for patients with relapsed and/or refractory non‐Hodgkin lymphoma (NHL) who are ineligible for transplantation or who have failed after bone marrow transplantation. The authors of this report investigated the safety and efficacy of clofarabine (CLO) in these patients.

METHODS:

In a 2‐step, open‐label study, CLO (as a 1‐hour intravenous infusion given daily for 5 days) was given every 28 days (maximum, 6 cycles). In the phase 1 portion (n = 7; standard 3 + 3 study design), the dose was escalated by 2 mg/m2 to determine the maximum tolerated dose (MTD). The phase 2 study (n = 26) was initiated at the MTD, and patients were followed until disease progression.

RESULTS:

Of 33 patients who were enrolled, 31 patients (median age, 69 years) were evaluable; 24% failed after previous stem cell transplantation, and 72% were rituximab‐refractory. The MTD for CLO was 4 mg/m2. The overall response rate was 42%. Seven patients (23%) achieved a complete response, and 6 patients (19%) achieved a partial response. The median response duration was 5 months. Among the rituximab‐refractory patients, the overall response rate was 47% (complete response rate, 28%), and the median response duration was 7 months. At a median follow‐up of 14 months, 45% of patients remained alive (median overall survival, 10 months). Toxicity was mainly hematologic (≥60% of patients had neutropenia or thrombocytopenia). Nonhematologic toxicity included tumor lysis syndrome, infection, and renal insufficiency (in 6% of patients each). No treatment‐related mortality was observed.

CONCLUSIONS:

Single‐agent CLO was active and was tolerated well in patients with refractory NHL, including patients in a rituximab‐refractory subset. Reversible myelosuppression was the major toxicity. Study is registered at www.clinicaltrials.gov (NCT00156013). Cancer 2011. © 2010 American Cancer Society.
Keywords:clofarabine  non‐Hodgkin lymphoma  rituximab‐refractory  refractory lymphoma  relapsed lymphoma
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号